1. <menuitem id="mw5yx"></menuitem>
      1. <tbody id="mw5yx"></tbody>

        <track id="mw5yx"></track>

              <tbody id="mw5yx"></tbody>

                A POWERFUL RESEARCH AND
                DEVELOPMENT ENGINE

                Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

                • Phase 1 trials

                  Phase 1 Trials

                  CEMIPLIMAB*

                  PD-1 Antibody
                  Cancer

                  REGN3767

                  LAG-3 Antibody
                  Cancer

                  REGN1979

                  CD20xCD3 Antibody
                  Cancer

                  REGN4018*

                  MUC16xCD3 Antibody
                  Cancer

                  REGN4659

                  CTLA4 Antibody
                  Cancer

                  REGN5458*

                  BCMAxCD3 Antibody
                  Cancer

                  REGN3048-3051

                  Middle East Respiratory Coronavirus Antibody
                  MERS-CoV infection

                  REGN4461

                  LEPR Antibody
                  Lipodystrophy and obesity

                  REGN5713-5714-5715

                  Betv1 Antibody
                  Birch Allergy
                • Phase 2 trials

                  Phase 2 Trials

                  CEMIPLIMAB*

                  PD-1 Antibody
                  Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
                  REGN1979
                  CD20xCD3 Antibody
                  Relapsed / refractory follicular lymphoma

                  DUPILUMAB*

                  IL-4R Antibody
                  Grass allergy, peanut allergy

                  SARILUMAB*

                  IL-6R Antibody
                  Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

                  REGN1908-1909

                  Fel d 1 Antibody
                  Cat allergy

                  REGN3500*

                  IL-33 Antibody
                  Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis

                  REGN5069

                  GFRα3 Antibody
                  Osteoarthritis knee pain

                  GARETOSMAB

                  Activin A Antibody
                  Fibrodysplasia Ossificans Progressiva (FOP)

                  EVINACUMAB

                  ANGPTL-3 Antibody
                  Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

                  POZELIMAB

                  C5 Antibody
                  Paroxysmal nocturnal hemoglobinuria
                • Phase 3 trials

                  Phase 3 Trials

                  AFLIBERCEPT
                  VEGF-Trap
                  Non-proliferative diabetic retinopathy (NPDR) without DME

                  ALIROCUMAB*

                  PCSK9 Antibody
                  Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

                  CEMIPLIMAB*

                  PD-1 Antibody
                  Non-small cell lung cancer, cervical cancer

                  REGN-EB3

                  Ebola Virus Antibody
                  Ebola virus infection

                  DUPILUMAB*

                  IL-4R Antibody
                  Atopic dermatitis in pediatrics, asthma in pediatric, eosinophilic esophagitis, COPD

                  SARILUMAB*

                  IL-6R Antibody
                  Polymyalgia rheumatica, giant cell arteritis

                  EVINACUMAB

                  ANGPTL-3 Antibody
                  Homozygous familial hypercholesterolemia (HoFH)

                  FASINUMAB?

                  NGF Antibody
                  Chronic pain from osteoarthritis of the knee or hip

                Trials Footnotes

                * in collaboration with Sanofi

                ? in collaboration with Teva and Mitsubishi Tanabe

                This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

                怡红院在线 视频免费